Patents by Inventor Norbert W. Bischofberger

Norbert W. Bischofberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5686629
    Abstract: An improved method for the preparation of acyclic nucleotide analogues comprises first condensing a cyclic carbonate with a purine or pyrimidine base and then reacting the alkylated base with an activated phosphonate. Novel cyclic carbonates are employed to yield the desired phosphonylmethoxyalkyl nucleotide analogues.
    Type: Grant
    Filed: December 27, 1995
    Date of Patent: November 11, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Kenneth M. Kent
  • Patent number: 5672697
    Abstract: Novel oligonucleotides analogs and nucleoside analogs as well as methods for their synthesis are described. The oligonucleotides are useful in diagnostic and therapeutic applications. The oligonucleotides are stable to nuclease degradation.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: September 30, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Chris Buhr, Mark Matteucci, Norbert W. Bischofberger, Brian Froehler
  • Patent number: 5514798
    Abstract: An improved method for the preparation of acyclic nucleotide analogues comprises first condensing a cyclic carbonate with a purine or pyrimidine base and then reacting the alkylated base with an activated phosphonate. Novel cyclic carbonates are employed to yield the desired phosphonylmethoxyalkyl nucleotide analogues.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: May 7, 1996
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Kenneth M. Kent
  • Patent number: 5175273
    Abstract: Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.
    Type: Grant
    Filed: July 1, 1988
    Date of Patent: December 29, 1992
    Assignee: Genentech, Inc.
    Inventors: Norbert W. Bischofberger, Mark D. Matteucci